Evidence map›Paper›PMID 41917471›Full record

ArticleActa pharmacologica Sinica2026

A novel CDK8/19 inhibitor RO8323 mitigates allograft rejection through dual mechanisms of action to modulate regulatory T cell and myeloid cell.

Fang Shen, Rou Xie, Ye Gan, Ping Ren, Ran-Ran Wu, Jia-Wei Yan, Yu-Ying Bian, Cheng-Cheng Liu, Song Yang, Xin-Chun Han and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Fang ShenChina Innovation Center of Roche, Shanghai, 201203, China.
Rou XieChina Innovation Center of Roche, Shanghai, 201203, China.
Ye GanChina Innovation Center of Roche, Shanghai, 201203, China.
Ping RenChina Innovation Center of Roche, Shanghai, 201203, China.
Ran-Ran WuChina Innovation Center of Roche, Shanghai, 201203, China.
Jia-Wei YanChina Innovation Center of Roche, Shanghai, 201203, China.
Yu-Ying BianChina Innovation Center of Roche, Shanghai, 201203, China.
Cheng-Cheng LiuChina Innovation Center of Roche, Shanghai, 201203, China.
Song YangChina Innovation Center of Roche, Shanghai, 201203, China.
Xin-Chun HanChina Innovation Center of Roche, Shanghai, 201203, China.
Chen-Gang ZhouChina Innovation Center of Roche, Shanghai, 201203, China.
Yao WuChina Innovation Center of Roche, Shanghai, 201203, China.
Yang TangChina Innovation Center of Roche, Shanghai, 201203, China.
Zhi-Heng XuChina Innovation Center of Roche, Shanghai, 201203, China.
Jun YangChina Innovation Center of Roche, Shanghai, 201203, China.
Hong-Xia QiuChina Innovation Center of Roche, Shanghai, 201203, China.
Ju-Hao YangChina Innovation Center of Roche, Shanghai, 201203, China.
Xue-Yan PuChina Innovation Center of Roche, Shanghai, 201203, China.
Li LiChina Innovation Center of Roche, Shanghai, 201203, China.
Yue GuiChina Innovation Center of Roche, Shanghai, 201203, China.
Gu-Liang XiaChina Innovation Center of Roche, Shanghai, 201203, China.
Kara G LassenPharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, 4070, Switzerland.
Hong C ShenChina Innovation Center of Roche, Shanghai, 201203, China.
Hao-Chu HuangChina Innovation Center of Roche, Shanghai, 201203, China. haochu.huang@roche.com.
Lue DaiChina Innovation Center of Roche, Shanghai, 201203, China. lue.dai.ld1@roche.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T (Treg) cells are pivotal in maintaining immune homeostasis through suppression of effector T (Teff) cells, making their therapeutic modulation a promising strategy for treating autoimmune and inflammatory diseases. CDK8/19 inhibitors promote Treg cell differentiation by upregulating Foxp3 expression in both naive and memory/effector T cells. In this study we identified a novel dual CDK8/19 inhibitor RO8323 and systematically dissected the mechanism of CDK8/19-mediated immunoregulation. RO8323 inhibited CDK8 and CDK19 with IC

Indexed as

Cyclin-Dependent Kinase 8Cyclin-Dependent KinasesGraft RejectionMyeloid CellsProtein Kinase InhibitorsT-Lymphocytes, RegulatoryAnimalsCell DifferentiationGraft vs Host DiseaseHeart TransplantationMiceMice, Inbred BALB CCDK19 protein, mouseCdk8 protein, mouseCyclin-Dependent Kinase 8Cyclin-Dependent KinasesProtein Kinase InhibitorsCDK8/19GVHDIL-10organ transplantationregulatory T cellsRO8323

Identifiers

PMID41917471
PMCPMC13388999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.